

Magnetic Luminex® Performance Assay Human G-CSF Kit

Catalog Number: LUHM214
Pack Size: 100 Tests

SPECIFICATIONS AND USE

Recommended Sample Types Microparticle Region Components

- Cell culture supernates, serum, EDTA plasma, and heparin plasma.
- Region-14
- Microparticle Concentrate (Part 894442) is supplied as a 100X concentrated stock (0.075 mL) with preservatives.
- Biotin-Antibody Concentrate (Part 892630) is supplied as a 100X concentrated stock solution (0.075 mL) with preservatives.

Other Supplies Required Storage


- Magnetic Luminex Performance Assay Human Base Kit A (Catalog Number LUHM000).
- Store the unopened kit at 2-8 °C. Do not use past the expiration date on the label.
- Avoid freezing microparticles.
- Protect microparticles from light.

Instructions for Use

• Refer to the Base Kit insert for the Luminex Performance Assay procedure.

TYPICAL DATA

This human G-CSF standard curve is provided only for demonstration. A standard curve must be generated each time an assay is run, utilizing values from the Standard Value Card included in the Base Kit.



Standard	pg/mL	MFI	Average	Corrected
Blank	0	13 13	13	
1	4500	8244 8301	8273	8260
2	1500	2809 2838	2824	2811
3	500	959 960	960	947
4	167	366 368	367	354
5	56	148 148	148	135
6	19	64 64	64	51
7	6	35 35	35	22

PERFORMANCE CHARACTERISTICS

All data were collected with assays run as a multiplex.

Data obtained with polystyrene and magnetic beads were equivalent.

Sensitivity - The Minimum Detectable Dose (MDD) was determined by adding two standard deviations to the MFI of twenty zero standard replicates and calculating the corresponding concentration.

Forty assays were evaluated, and the MDD of human G-CSF ranged from 0.19-1.48 pg/mL. The mean MDD was 0.57 pg/mL.

752778.0

Intra-assay Precision (precision within an assay) - Three samples of known concentration were tested twenty times on one plate to assess precision within an assay.

Inter-assay Precision (precision between assays) - Three samples of known concentration were tested in twenty separate assays to assess precision between assays.

	Int	Intra-assay Precision			In	ter-assay Precis	sion
Sample	1	2	3		1	2	3
n	20	20	20		20	20	20
Mean (pg/mL)	17.1	31.7	508		20.1	240	440
Standard Deviation	1.2	2.1	10.9		1.9	33	22
% CV	7.1	5.3	2.1		9.5	13.9	4.9

Recovery and Linearity – Samples containing and/or spiked with high concentrations of G-CSF were evaluated for recovery and were serially diluted to evaluate assay linearity.

Recovery					
Sample Type	Average % Recovery	Range (%)			
Cell culture supernates	95	75-110			
Serum	102	88-113			
EDTA plasma	91	62-117			
Heparin plasma	88	77-101			

Linearity							
	Cell culture supernates	Serum	EDTA Plasma	Heparin Plasma			
Average % of Expected	103	109	106	113			
Range (%)	90-113	100-115	82-118	105-122			
Average % of Expected	110	107	107	114			
Range (%)	84-131	85-120	70-122	108-119			
Average % of Expected	114	113	117	114			
Range (%)	80-138	85-129	102-129	111-123			
	Range (%) Average % of Expected Range (%) Average % of Expected	Cell culture supernates Average % of Expected 103 Range (%) 90-113 Average % of Expected 110 Range (%) 84-131 Average % of Expected 114	Cell culture supernates Serum Average % of Expected 103 109 Range (%) 90-113 100-115 Average % of Expected 110 107 Range (%) 84-131 85-120 Average % of Expected 114 113	Cell culture supernates Serum EDTA Plasma Average % of Expected 103 109 106 Range (%) 90-113 100-115 82-118 Average % of Expected 110 107 107 Range (%) 84-131 85-120 70-122 Average % of Expected 114 113 117			

Specificity - This assay recognizes natural and recombinant human G-CSF. The assay was tested for cross-reactivity and interference with the following factors. Less than 0.5% cross-reactivity and interference was observed.

Recombinant human:			Recombinant mouse:		Recombinant rat:	Recombinant porcine:	Recombinant human multiplex partners:	
6Ckine	IL-1 RII	IL-17	G-CSF	IL-8	GM-CSF	GM-CSF	ENA-78	IL-8
CNTF	IL-2 R $lpha$	IL-18	GM-CSF	IL-10	IFN-γ	IL-1 α	FGF basic	IL-10
β-ECGF	IL-2 Rβ	LIF	IFN-γ	IL-17	IL-1α	IL-1β	GM-CSF	IL-17
FGF acidic	IL-2 Rγ	LIF R	IL-1α	MIP-1 α	IL-1β	IL-2	IFN-γ	MCP-1
FGF-4	IL-3 Rα	MIP-1 $lpha$	IL-1ra	MIP-1β	IL-2	IL-4	IL-1α	MIP-1 $lpha$
FGF-5	IL-4 R	MIP-3 $lpha$	IL-1	RANTES	IL-4	IL-6	IL-1β	MIP-1β
FGF-6	IL-5 R $lpha$	MIP-3β	IL-2	Тро	IL-6	IL-8	IL-1ra	RANTES
FGF-9	IL-6 R	MCP-2	IL-4	TNF-α	IL-10	IL-10	IL-2	Тро
FGF-10	IL-10 R	MCP-3	IL-5	VEGF	TNF- $lpha$	Leptin	IL-4	TNF-α
FGF-18	IL-3	MCP-4	IL-6			TNF-α	IL-5	VEGF
GCP-2	IL-7	M-CSF					IL-6	
$GR0\alpha$	IL-9	TNF RI						
GR0β	IL-11	TNF- $lpha$						
GROγ	IL-12 p40	VEGF ₁₂₁						
I-309	IL-12 p70	VEGF ₁₆₅						
IGF-I	IL-13	VEGF-D						
IGF-II	IL-15							
IL-1 RI	IL-16							

TECHNICAL HINTS

- Protect the microparticles and streptavidin-PE from light at all times.
- Refer to the Base Kit Standard Value Card for reconstitution volume and values of the reconstituted standard.
- Diluted microparticles cannot be stored. Make a fresh dilution of microparticles each time the assay is run.
- The use of a magnetic device made to accommodate a microplate is necessary for washing.
- Discrepancies may exist in values obtained for the same analyte utilizing different technologies.

Luminex Performance Assays afford the user the benefit of multianalyte analysis of biomarkers in a complex sample. For each sample type, a single, multipurpose diluent is used to optimize recovery, linearity, and reproducibility. Such a multipurpose diluent may not optimize any single analyte to the same degree that a unique diluent selected for analysis of that analyte can optimize conditions. Therefore, some performance characteristics may be more variable than those for assays designed specifically for single analyte analysis.

752778.0 www.RnDSystems.com